Vamikibart for Uveitic Macular Edema
(Sandcat Trial)
Trial Summary
What is the purpose of this trial?
This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have used certain eye treatments like IVT biologics, Methotrexate, or specific implants within a certain period before the trial starts.
Will I have to stop taking my current medications?
The trial does not specify if you must stop all current medications, but it does mention that certain eye treatments like specific injections or implants should not have been used recently. It's best to discuss your current medications with the trial team to see if they are allowed.
What data supports the idea that Vamikibart for Uveitic Macular Edema is an effective treatment?
The available research does not provide specific data on Vamikibart for Uveitic Macular Edema. Instead, it focuses on other treatments for different types of macular edema, such as aflibercept and pegaptanib, which are used for conditions like branch retinal vein occlusion. Without direct data on Vamikibart, we cannot conclude its effectiveness for Uveitic Macular Edema based on the provided information.12345
What safety data is available for Vamikibart (RO7200220) in treating uveitic macular edema?
The provided research does not contain any safety data for Vamikibart (RO7200220) or its other names (RG-6179, RO-7200220) in the treatment of uveitic macular edema. The studies focus on other treatments for macular edema, such as ranibizumab, aflibercept, conbercept, and fingolimod, but do not mention Vamikibart.36789
Is the drug Vamikibart a promising treatment for Uveitic Macular Edema?
Research Team
Clinical Trials
Principal Investigator
Hoffmann-LaRoche
Eligibility Criteria
This trial is for women with uveitic macular edema, which causes swelling in the eye. They must have a certain level of vision impairment and agree to use contraception or abstain from sex. Those with recent major eye surgeries, infections like syphilis or tuberculosis, HIV, uncontrolled glaucoma, or who've used certain medications recently can't join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 4 intravitreal injections every 4 weeks up to Week 12, followed by as-needed dosing from Week 20 to Week 48
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- RO7200220
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hoffmann-La Roche
Lead Sponsor
Dr. Levi Garraway
Hoffmann-La Roche
Chief Medical Officer since 2019
MD from the University of Basel
Dr. Thomas Schinecker
Hoffmann-La Roche
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University